BREVEL

Their core work

BREVEL is an Israeli deep-tech SME that develops and commercializes advanced photobioreactor systems for industrial microalgae cultivation. Their core innovation is a proprietary internally-illuminated bioreactor that enables high-density, scalable growth of microalgae for producing high-value compounds such as astaxanthin — a premium antioxidant used in nutraceuticals, aquaculture feed, and cosmetics. They apply mixotrophic cultivation strategies that combine photosynthesis with organic carbon feeding, achieving yields that conventional open-pond or surface-illuminated bioreactor systems cannot match. Their trajectory — from a EUR 50,000 feasibility grant to a EUR 1.17 million scale-up project — shows a company moving rapidly from prototype to industrial production.

What they specialise in

How they've shifted over time

BREVEL's first H2020 project in 2018 was a proof-of-concept feasibility study focused on the solar-illumination mechanism of the bioreactor itself — the technology platform rather than any specific product. By 2020, the focus had sharpened to industrial scale-up with explicit commercial targets: astaxanthin as the lead product and mixotrophy as the enabling cultivation method. The shift from undefined-keyword feasibility to product-specific scale-up is a clean, deliberate progression typical of a startup moving from technology validation to market entry.

BREVEL is on a commercialization path — their next logical step is either a Series A/B funding round or a manufacturing partnership to bring industrial-volume astaxanthin to market, making them an attractive partner for food ingredient companies, aquaculture producers, or nutraceutical manufacturers.

How they like to work

BREVEL has acted as sole coordinator on both its EU projects, with no recorded consortium partners — a pattern typical of SME Instrument grants, which are designed for single companies demonstrating their own technology. This means they have no established EU consortium network and have not been tested as a consortium partner. Anyone considering them as a project partner would be working with a company whose strengths lie in executing focused, company-internal R&D rather than managing large multi-partner collaborations.

BREVEL has no recorded external H2020 consortium partners and has collaborated with no other countries through EU funding. Their EU track record is purely solo SME Instrument activity, so their scientific and industrial network — which likely exists through Israeli academia and the private sector — is not visible in this dataset.

What sets them apart

BREVEL occupies a rare niche: a commercially-oriented Israeli SME that has twice secured EU SME Instrument funding for a single coherent technology — internally-illuminated photobioreactors for high-value algae compounds. Unlike research institutes that produce papers, or large biotech firms with broad portfolios, BREVEL is a focused product company with a specific scalable technology and one primary commercial target (astaxanthin). For a consortium that needs a credible industrial partner in microalgae bioprocessing with demonstrated EU grant execution, BREVEL is one of very few options combining Israeli R&D culture with direct EU funding experience.

Highlights from their portfolio

• BREVEL
  The largest award (EUR 1,173,123, SME Phase 2) represents a full industrial scale-up commitment and is the clearest signal of BREVEL's commercial maturity — EU evaluators judged the technology ready for market demonstration.
• Brevel
  The 2018 SME Phase 1 feasibility grant (EUR 50,000) is notable as the origin point: it established the solar-illuminated bioreactor concept that the company then scaled, making it the seed of the entire commercial trajectory.